Latest News for: bladder cancer

Edit

TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Nasdaq Globe Newswire 23 Feb 2026
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events ... .
Edit

Penn Highlands Brookville offers innovative bladder cancer therapy

Courier Express 20 Feb 2026
BROOKVILLE — Bladder cancer is the sixth most common cancer in the U.S. People diagnosed with bladder cancer in northwestern Pennsylvania have access to a new therapy that helps send it into remission and Penn Highlands Brookville is only the ....
Edit

Cells that communicate may help hinder bladder cancer from spreading (University of York)

Public Technologies 19 Feb 2026
) Cells that communicate may help hinder bladder cancer from spreading ... "When we then studied a group of aggressive bladder (urothelial) cancers, we found that patterns of Cx32 protein were informative for understanding tumour behaviour.
Edit

Muscle Invasive Bladder Cancer Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | ...

GetNews 19 Feb 2026
DelveInsight’s “Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Muscle Invasive Bladder Cancer, ...
Edit

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

Pharmiweb 18 Feb 2026
Bladder cancer represents a significant public health burden in the European Union, ranking as the fifth most common cancer overall and the seventh most frequently diagnosed cancer among men.1,2 The ...
Edit

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries (Form 8-K) (Immunitybio Inc)

Public Technologies 18 Feb 2026
for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer ... The European Association of Urology and the World Bladder Cancer Patient Coalition estimate that more than 200,000 new cases of bladder cancer will be diagnosed in 2025.
Edit

Bladder cancer patients offered survival hope by new drug greenlit on NHS

The Daily Mail 15 Feb 2026
Studies show durvalumab can halt progression of the muscle-invasive form of the disease and prevent further hospitalisation ....
Edit

Before Bladder Cancer, Vinod Khanna Survived Lung Cancer Diagnosis, Says Wife

NDTV 11 Feb 2026
Vinod Khanna's wife said, "It was 2001 when Vinod had a diagnosis of lung cancer" ... .
Edit

Bladder Cancer Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Bristol-Myers Squibb ...

GetNews 10 Feb 2026
DelveInsight’s “Bladder Cancer Market Insights, ... Bladder Cancer current marketed and Bladder Cancer emerging therapies ... Bladder Cancer market drivers and Bladder Cancer market barriers.
Edit

Not just bladder cancer, Vinod Khanna also battled lung cancer, reveals wife: ‘He’d smoke 40 ...

Hindustan Times 09 Feb 2026
. Bollywood ....
Edit

Muscle Invasive Bladder Cancer Competitive Landscape: Insights Into 10+ Companies, 10+ Pipeline Drugs, and Phase ...

GetNews 09 Feb 2026
Key Highlights from the Muscle Invasive Bladder Cancer Pipeline Report MIBC Companies worldwide are actively engaged in developing more than 10 innovative therapies for Muscle Invasive Bladder Cancer, achieving meaningful progress over time.
Edit

Colorblindness May Increase The Risk Of Dying From Bladder Cancer

IFL Science 29 Jan 2026
The team, including researchers from Stanford University, looked at the mortality rates of people with CVD in both bladder cancer and colorectal cancer ... Other symptoms of bladder cancer include pain, ...
Edit

Chugai Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer (Chugai Pharmaceutical Co Ltd)

Public Technologies 28 Jan 2026
Muscle-invasive bladder cancer (MIBC) is a type of bladder cancer, and about 25% of bladder cancers are MIBC.1) The annual incidence of MIBC in Japan is estimated to be approximately 6,000 cases as of ...
Edit

4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer

Nasdaq Globe Newswire 22 Jan 2026
4D Path to participate as exploratory biomarker collaborator in Phase II DAD-IO clinical study (NCT04724018) led by DFCI and supported by Gilead Sciences ... .
Edit

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

Pharmiweb 20 Jan 2026
FDA regarding the Company’s supplemental Biologics License Application (sBLA) for ANKTIVA® (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors.

Article Search

tools
×
×
×
×